Stephanie Tubbs Jones Uterine Fibroid Research and Education Act of 2023
2/5/2024, 2:30 PMSummary of Bill HR 4572
Bill 118 HR 4572, also known as the Stephanie Tubbs Jones Uterine Fibroid Research and Education Act of 2023, is a piece of legislation introduced in the US Congress with the aim of addressing the issue of uterine fibroids. Uterine fibroids are non-cancerous growths that develop in the uterus and can cause a variety of symptoms such as heavy menstrual bleeding, pelvic pain, and infertility.The bill proposes to allocate funding for research into the causes and treatment of uterine fibroids, as well as for educational programs aimed at raising awareness about the condition. The goal of the legislation is to improve the diagnosis and treatment of uterine fibroids, as well as to increase access to care for women affected by the condition.
If passed, the Stephanie Tubbs Jones Uterine Fibroid Research and Education Act of 2023 would represent a significant step forward in addressing a common and often debilitating health issue that affects many women in the United States. The bill has garnered bipartisan support and is currently being considered by Congress.
Congressional Summary of HR 4572
Stephanie Tubbs Jones Uterine Fibroid Research and Education Act of 2023
This bill directs the Department of Health and Human Services (HHS) to expand research on, and take other actions to address, uterine fibroids. These are muscular tumors that grow in the wall of the uterus and may cause pain, heavy menstrual bleeding, and reproductive issues.
In coordination with the National Institutes of Health and appropriate federal agencies, HHS must undertake research activities on uterine fibroids.
In addition, HHS must establish a database of services furnished to individuals diagnosed with uterine fibroids under Medicaid or the Children's Health Insurance Program and must develop a report on federal and state expenditures for such services.
Additionally, HHS must disseminate information on uterine fibroids to the public and to health care providers, including information on the elevated risk for minority women and available treatments.
